ACTRIMS Forum 2026 (Americas Committee for Treatment and Research in Multiple Sclerosis) (Videos + Slides)

ACTRIMS Forum 2026 examines multiple sclerosis at a point of change in disease biology, diagnosis and treatment. Held February 5–7 in San Diego under the theme “MS at a Crossroads,” the meeting used a single-track program to connect emerging research with clinical questions. Sessions address susceptibility, intervention, new technologies, disease-course descriptions and late-breaking trial findings. The program also includes partner symposia and the Kenneth P. Johnson Memorial Lecture, delivered by Jeffrey Cohen, MD, of Cleveland Clinic. This MedicalAmboss listing provides videos and slides for reviewing the included scientific and clinical material.

Package scope: The original venue was Marriott Marquis San Diego Marina. The agenda includes conference activities and more than 400 advertised posters; their appearance here does not establish recording or poster coverage in the package. ACTRIMS registration, the Event App, LearnMS access and continuing-certification credit are not included.

Program leadership: Daniel Reich, MD, PhD, National Institutes of Health / National Institute of Neurological Disorders and Stroke, chaired the committee, with Jiwon Oh, MD, University of Toronto, as vice-chair. Agenda times are Pacific Standard Time.

Major Topics Covered

• Multiple Sclerosis
• Neuroimmunology
• CNS Inflammatory Disease
• Demyelinating Disorders
• MS Pathogenesis
• MS Immunology
• Disease Mechanisms
• Neuroinflammation
• B-Cell Biology
• T-Cell Biology
• Microglia
• Neurodegeneration
• Demyelination
• Axonal Injury
• MS Genetics
• Environmental Risk Factors
• MS Biomarkers
• Blood Biomarkers
• CSF Biomarkers
• MRI Biomarkers
• Advanced Neuroimaging
• MS Diagnosis
• Disease Progression
• Progression Independent of Relapse Activity
• Progressive Multiple Sclerosis
• Disease-Modifying Therapies
• High-Efficacy Therapy
• Treatment Sequencing
• Treatment Switching
• Treatment De-escalation
• MS Treatment Safety
• Personalized MS Therapy
• MS Clinical Trials
• New Therapeutic Targets
• Neuroprotection
• Remyelination
• Neural Repair
• Translational Neuroscience
• Cutting-Edge Research
• Late-Breaking Research
• Young Investigator Research
• Scientific Posters
• Future Directions in Multiple Sclerosis

Thu, Feb 5, 2026

• 7:30 AM9:00 AM Breakfast in the Hub
• 8:00 AM9:00 AM SS1. Industry Supported Satellite Symposium 1 – Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment Decisions
• 9:00 AM9:15 AM Break
• 9:15 AM10:15 AM Welcome & Kenneth P. Johnson Memorial Lecture
• 10:15 AM10:30 AM Break
• 10:30 AM12:05 PM S1. Session 1 – Emerging Concepts in MS
• 12:05 PM1:30 PM Lunch in the Hub
• 12:30 PM1:15 PM Brain Exchange Community Discussion 1 – Cell Therapy
• 1:30 PM2:30 PM AP1. Partner Symposium – NAIMS: Is Brain Atrophy at a Crossroads for Use as Outcome Measure in Clinical Trials?
• 2:30 PM2:45 PM Break
• 2:45 PM4:15 PM S2. Session 2 – From Susceptibility to Symptoms: Rethinking MS Intervention
• 4:15 PM4:30 PM Break
• 4:30 PM5:35 PM CE1. Cutting Edge Developments 1
• 5:45 PM7:30 PM Poster Session 1
• 7:45 PM9:00 PM iWiMS Event

Fri, Feb 6, 2026

• 7:00 AM7:45 AM ACTRIMS Forum 2026 Wellness Walk
• 7:30 AM9:00 AM Breakfast in the Hub
• 8:00 AM9:00 AM SS2. Industry Supported Satellite Symposium 2 – Neuroinflammation in Focus: Interpreting the Latest Evidence for BTK Inhibition in Multiple Sclerosis
• 8:15 AM9:00 AM Brain Exchange Community Discussion 2 – National MS Brain Bank Cases
• 9:00 AM9:15 AM Break
• 9:15 AM10:15 AM BP1. National MS Society Barancik Award Presentation & Talk
• 10:15 AM10:30 AM Break
• 10:30 AM12:00 PM S3. Session 3 – Emerging Biologies: Charting New Directions
• 12:00 PM1:30 PM Lunch in the Hub
• 12:20 PM1:20 PM SS3. Industry Supported Satellite Symposium 3 – How Do I Identify MOGAD?
• 12:30 PM1:15 PM Brain Exchange Community Discussion 3 – Funding Landscapes
• 1:30 PM2:30 PM AP2. Partner Symposium – IMSVISUAL: AI-Driven Diagnostics and Pathways of Neurodegeneration Using the Visual Pathway in Demyelinating Disease
• 2:30 PM2:45 PM Break
• 2:45 PM4:15 PM S4. Session 4 – New Technologies: Shifting the Paradigm?
• 4:15 PM4:30 PM Break
• 4:30 PM5:35 PM CE2. Cutting Edge Developments 2
• 5:45 PM7:30 PM Poster Session 2

Sat, Feb 7, 2026

• 7:30 AM9:00 AM Breakfast
• 8:00 AM9:00 AM AP3. Partner Symposium – European Charcot Foundation – Dynamics in MS Across the Lifespan
• 9:00 AM9:30 AM AP4. Partner Invited Lecture – LACTRIMS – Menopause, MS and Progression
• 9:30 AM9:40 AM Break
• 9:40 AM11:10 AM S5. Session 5 – Rethinking MS Clinical Course Descriptors
• 11:10 AM11:20 AM Break
• 11:20 AM11:30 AM Awards Presentation
• 11:30 AM12:40 PM LB1. Late-Breaking Research & Clinical Trials
• 12:40 PM12:45 PM Closing